Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.


CSE:BRAX - Post by User

Comment by LukeCoolHandson Sep 01, 2020 6:35pm
171 Views
Post# 31491286

RE:RE:RE:LCH June 19th

RE:RE:RE:LCH June 19th
Esketamine is awesome and would provide great revenue IF they were going to use their patented proprietary method to administer ketamine -like they praised when false partnering with the Orange County clinic in California. Ironically, the day they get slapped a new HALT- Their 1 clinic decides after months and months to treat with J&J's esketamine? NO clinic needed in US. Just a prescription. What might create revenue (besides for Johnson&Johnson) is public trust. Having competent employees that don't cause quarterly long securities halts is a start... Maybe sell some unadvertised tea...Open another clinic...Get Doc a YouTube channel...Wash cars...IDK...Start curing PSTD instead of causing it!
<< Previous
Bullboard Posts
Next >>